What dGenThera does

dGenThera is a preclinical-stage radiopharmaceutical company headquartered in Durham, North Carolina, developing a pipeline of theranostic molecular pairs for targeted cancer therapy. The company's central technology is a proprietary carbon-halogen bond stabilization platform — developed at the University of North Carolina Chapel Hill — that enables stable in vivo incorporation of Astatine-211 and Iodine-131 by preventing dehalogenation, a historical failure mode that has constrained halogen-based radiotherapeutics. Combined with a proprietary F-18 installation chemistry, the platform produces 'exquisitely matched' theranostic triplets in which Fluorine-18 PET diagnostics and At-211/I-131 therapeutics share a common molecular scaffold and differ only in their isotope label, enabling faithful biodistribution reporting and predictable single-particle alpha dosimetry.

The pipeline is organized into two tracks. The small-molecule track develops transporter-substrate radiotherapeutics (~500 amu) designed to accumulate in tumor cells and cross the blood-brain barrier for brain cancer and metastasis indications; lead candidate 211At-DGT-77 demonstrated approximately 100% tumor growth inhibition at four weeks following a single 2 MBq dose (>98% radiochemical purity) in a breast cancer xenograft model. The bioligand-tag track uses small, diverse, chemically tunable tags to construct radio-labeled conjugates with matched physicochemical properties; lead asset 131I-DGT-207 showed superior biodistribution versus chelated-metal targeted radiotherapeutics and other I-131 designs in undisclosed human cancer xenograft studies. The competitive framing is targeted solid tumors and brain tumors, differentiated versus chelated metal emitters (Ac-225, Pb-212) on stability, dosimetry predictability, and brain exposure.

The company is pre-revenue and commercialization is not yet underway. GTM is organized around enterprise partnerships with isotope producers and CDMOs to secure At-211 supply (Nusano via accelerator production, LOI June 2025; Alpha Nuclide via vertically integrated Chinese infrastructure, strategic partnership March 2026) and clinical-translation capability, with an ultimate revenue model oriented toward out-licensing or partnering pipeline assets for development and commercialization. Targeted customer segments at this stage are isotope suppliers, pharmaceutical collaborators, and nuclear medicine clinical sites rather than providers or payors.

Name

dGenThera

Legal name

dGenThera, Inc.

Website

https://dgenthera.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

dGenThera is a preclinical-stage radiopharmaceutical company developing matched theranostic molecular pairs using Astatine-211, Iodine-131, and Fluorine-18, stabilized by proprietary carbon-halogen bond chemistry, to deliver image-guided targeted radiotherapy for high-unmet-need solid tumors and brain cancers.

Ownership category

akta.pro rank

Product category

Targeted Radiotherapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

Keywords

• Targeted radiotherapeutics
• Theranostic drug pairs
• Radiopharmaceutical pipeline
• Alpha emitter oncology
• Preclinical radioisotope therapy

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Radiopharmaceutical Pipeline: dGenThera is a pre-clinical/clinical stage biopharmaceutical company developing a pipeline of theranostic agents for cancer treatment. The company is advancing assets through development toward commercialization, targeting high-unmet-need cancer indications including solid tumors and brain cancers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

dGenThera develops a pipeline of theranostic radiopharmaceutical drug candidates built on a proprietary chemistry platform that pairs Fluorine-18 PET imaging agents with Astatine-211 or Iodine-131 therapeutic agents on the same molecular scaffold. Its lead preclinical candidates are the small-molecule agent 211At-DGT-77 (demonstrating approximately 100% tumor growth inhibition in breast cancer xenograft models) and the bioligand-tagged asset 131I-DGT-207, both stabilized against in vivo dehalogenation to enable targeted delivery to solid tumors including those in the brain.

Product overview

dGenThera is a next-generation targeted radiotherapeutics company advancing a differentiated pipeline of theranostic agents for precision oncology. The company's core offering is its proprietary chemistry platform that creates exquisitely matched theranostic molecular pairs—using Fluorine-18 for PET imaging and Astatine-211 (At-211) or Iodine-131 (I-131) for therapy—differing only in their isotope label. The platform is built on two key technology foundations: carbon-halogen bond stabilization technology that prevents in vivo dehalogenation (hitherto a major limitation of halogen emitters), and F-18 installation technology developed at UNC Chapel Hill. The company's pipeline consists of small molecule radiotherapeutics (including lead candidate 211At-DGT-77) and bioligand-tag conjugates (including 131I-DGT-207), targeting multiple high-unmet-need cancer indications including solid tumors and brain cancers. dGenThera's approach enables true image-guided targeted radiotherapy where diagnostic and therapeutic forms behave nearly identically in the body, facilitating seamless integration with existing nuclear medicine workflows.

Differentiator

Problem solved

Functional benefit

Products and services

• 211At-DGT-77 (lead small molecule radiotherapeutic) Preclinical lead small-molecule At-211 radiotherapeutic; transporter substrate designed to accumulate in tumor cells, target solid tumors, and cross the blood-brain barrier. Demonstrated ~100% tumor growth inhibition at 4 weeks in breast cancer xenograft model at >98% radiochemical purity.
• 131I-DGT-207 (lead bioligand-tagged radiotherapeutic) Preclinical lead bioligand-tagged radiotherapeutic candidate radiolabeled with Iodine-131; pairs a small (~500 amu) proprietary tag with a tumor-targeting fusion partner to enable superior biodistribution versus chelated-metal TRTs and other I-131 TRTs for the same target.
• Small Molecule Radiotherapeutic Pipeline Pipeline of transporter-substrate small-molecule radiotherapeutics (~500 amu) designed to accumulate in tumor cells, target multiple solid tumors, and cross the blood-brain barrier for cancer indications.
• Bioligand-Tag Conjugate Pipeline Pipeline of radio-labeled bioligand-tag conjugates using small (~500 amu) proprietary tags with multiple attachment chemistries, where physicochemical properties are matched to tumor-targeting fusion partners for enhanced biodistribution and efficacy.

Quantifiable outcome

• 100% tumor growth inhibition (TGI) at four weeks post-dosing in breast cancer xenograft model
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Alpha Nuclide Co, LTDcoreStrategic or Co-development Partner · 10 March 2026Strategic partnership to secure reliable and scalable supply of Astatine-211 (At-211) for radiopharmaceutical development targeting cancer treatment. Alpha Nuclide operates advanced multi-site production facilities in Eastern China (Jiaxing/Shanghai region) and will open a North China production center in Shijiazhuang in 2028. The agreement provides dGenThera access to Alpha Nuclide's vertically integrated infrastructure including At-211 supply, preclinical CRO services, and clinical CDMO capabilities.
• NusanocoreStrategic or Co-development Partner · 19 June 2025Letter of Intent for Astatine-211 (At-211) supply. Nusano will supply dGenThera with At-211 in quantities sufficient to enable ongoing preclinical studies, first-in-human trials, and subsequent clinical development. Nusano's breakthrough accelerator technology in Salt Lake City region can produce 100-times increase in the world's total At-211 supply with alpha beam current 10-times greater than all comparable systems combined.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Bayer: Bayer markets Xofigo (Ra-223), an alpha-emitting radiotherapeutic for prostate cancer bone metastases, and has a broader radiopharmaceutical platform through its Algeta heritage. It is a relevant incumbent in targeted alpha therapy where dGenThera competes.
• Lantheus Holdings: Lantheus is a leading radiopharmaceutical company with a portfolio including diagnostic imaging agents and a growing targeted radiotherapeutic pipeline (e.g., PNT2002/Somakit-TOC). It competes in the same theranostic and radioligand imaging/therapy market that dGenThera addresses.
• Novartis: Novartis commercializes Pluvicto (Lu-177 PSMA) and Lutathera (Lu-177), the leading FDA-approved targeted radioligand therapies. It is the dominant incumbent in the theranostic and targeted radiotherapeutic space that dGenThera is entering, though Novartis is focused on Lu-177 / beta emitters rather than the At-211 alpha emitter niche dGenThera pursues.

Emerging players

• Aktis Oncology: Aktis Oncology is a private radiopharmaceutical company developing alpha-emitter targeted radiotherapeutics. It is a directly comparable emerging player with a similar preclinical/early-clinical stage profile, focused on the same oncology indications as dGenThera.
• ARTBIO: ARTBIO is an emerging radiopharmaceutical company specifically focused on alpha emitters (Pb-212) and is developing proprietary isotope production plus targeted alpha therapy candidates. It directly competes with dGenThera in the alpha-emitter targeted radiotherapy space.

Direct peers

• Point Biopharma: Point Biopharma developed Lu-177-based radioligand therapies (e.g., PNT2003) and was acquired by Eli Lilly in 2024 for ~$1.4B. It is a directly comparable targeted radiotherapeutic peer whose exit illustrates the M&A appetite for radiopharma platforms.
• Telix Pharmaceuticals: Telix develops and commercializes diagnostic and therapeutic radiopharmaceuticals (e.g., Illuccix for PSMA PET imaging) and is actively expanding into targeted radioligand therapy. It is one of the closest publicly traded comparables to dGenThera's theranostic platform approach.
• RayzeBio: RayzeBio developed actinium-225-based targeted radiotherapeutics and was acquired by Bristol Myers Squibb in 2024 for ~$4.1B. It is the most relevant recent alpha-emitter targeted radiotherapeutic peer and a strong valuation precedent for the At-211 niche dGenThera addresses.
• ITM Isotope Technologies Munich: ITM is a radiopharmaceutical company developing both diagnostic and therapeutic radioisotope-based products (notably Lu-177-based therapies) and is building isotope production capacity. It directly overlaps dGenThera's theranostic and isotope-supply model.
• Fusion Pharmaceuticals: Fusion developed targeted alpha therapies (Ac-225-based conjugates) and was acquired by AstraZeneca in 2024 for ~$2.4B. It is a near-direct historical peer in alpha-emitter targeted radiotherapeutics and a relevant valuation reference point for At-211 platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/dGenThera
• LinkedInlinkedin.com/company/dgenthera

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about dGenThera